- About
- Research
- Our research units
- Clinical Trials Unit at Midland
Clinical Trials Unit at Midland
In addition to good clinical practice training, our dedicated team members deliver excellence for patients and industry sponsors through on-going mandatory training and competency assessment requirements for research nursing preceptorships, informed consent, recruitment and retention as well as phlebotomy and laboratory processing.
We value our patient’s voluntary participation in clinical trials that is essential in further refining current and developing medicines, medical devices, and therapies. Here at CTU Midland, we extend the healing mission of Jesus to our participants by providing them exclusive access to pioneering treatments and personalised enhanced care throughout their medical journey with us. Participants’ safety and wellbeing is our utmost priority, hence trials listed below have been endorsed by St John of God Health Care’s Human Research Ethics Committee and St John of God Midland Public and Private Hospital’s Research Advisory Committee prior to commencement of participant recruitment.
Contact us at [email protected] to find out more about the trials currently recruiting new participants, or if you’re interested in being contacted for future trials.
Commencing November 2025
TV53408-IMM-20042
A multicentre, randomized, double-blind, placebo-controlled, phase 2a trial to characterize the efficacy and safety of TEV-53408 in adults with celiac disease while undergoing oral gluten exposure
Principal investigator: Dr. Michael Lim
Sponsor: Teva Branded Pharmaceutical
TAK-101-2001
A randomized, double-blind, placebo-controlled, phase 2 dose ranging study to evaluate the efficacy and safety of TAK-101 for the prevention of gluten-specific T cell activation in subjects with celiac disease on a gluten-free diet
Principal investigator: Dr. Michael Lim
Sponsor: Takeda Development Center Americas, Inc.
KAN-101-02
A phase 1b open-label/phase 2 double-blind placebo-controlled study for pharmacodynamic activity, pharmacokinetics, safety and tolerability of KAN-101 in patients with celiac disease
Principal investigator: Dr. Michael Lim
Sponsor: Kanyos Bio, Inc., a wholly owned subsidiary of Anokion S. A.
CC-93538-EE-002
A phase 3, multicentre, multinational, open-label extension study to evaluate the long-term safety of CC-93538 in adult and adolescent subjects with eosinophilic esophagitis
Principal investigator: Dr. Ajay Sharma
Sponsor: Celgene International II Sàrl
CC-93538-EE-001
A phase 3, multicentre, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC-93538 in adult and adolescent subjects with eosinophilic esophagitis
Principal investigator: Dr. Ajay Sharma
Sponsor: Celgene International II Sàrl
Information for pharmaceutical sponsors and contract research organisation (CRO)
Clinical Trial Unit at Midland welcomes all trials from phase I to phase IV.
Our therapeutic areas of interest
- gastroenterology – paediatric and adult
- infectious diseases
- neurology
- paediatrics
- respiratory
- stroke
Services
Our Clinical Trial Unit has:
- A centralised trial laboratory equipped with refrigerated centrifuge, refrigerator, freezers, incubator, and laminar fume hood.
- Access to dedicated vital signs machine, ECG machine, IV infusion pumps.
- ICH GCP E6 (R3) and IATA certified team.
- A growing range of operational SOPs and guidelines (available upon request).
- Assigned HPS pharmacists for drug reconstitution.
- Inhouse third party radiology and laboratory facilities.
- Access to patients within the East Metro, Wheatbelt regions and beyond.
Clinical Trials Unit
- Dr. Benjamin Kan – Research Operations Manager
- Nadzirah Bashir – Senior Clinical Trials and Data Management Officer
- Susan Masters – Clinical Research Nurse
- Berliana Kurniawati – Research Registered Nurse
Contact for site partnership
- Clinical Trials Unit: [email protected]
- Midland Research Office: [email protected]
You may be interested in...